Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose olanzapine for prevention and treatment of carboplatin-induced nausea and vomiting
ChiCTR2000040566Phase 4Recruiting
- Sponsor
- Ordos Central Hospital
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Ordos Central Hospital. Primary endpoints: Overall phase complete response, Functional Living Index-Emesis scale and 3 more. Started Dec 2020; status: recruiting.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2000040566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040566.